Clinic sale anatomy: only 42% of CPP Europe deals paid in cash

Newly filed UK accounts expose how clinic consolidation deals are structured, with most value deferred or contingent rather than paid at completion.

By Disrupts Editorial Team Mon, 17 August 2026

A brightly lit data center aisle features rows of server racks with glowing blue indicator lights, intertwined with numerous colorful red, blue, green, and yellow network cables in the foreground, receding into a hazy, bright background wit

A close reading of CPP Europe's first statutory accounts has surfaced a structural detail that independent clinic owners rarely see before signing: of the £54.9 million in total headline consideration across ten UK and Irish acquisitions, only £23.1 million, or 42%, was cash paid at completion. The rest was divided between shares in the buyer (27%), profit-share arrangements running for up to 30 years (17%), and earn-out payments tied to future clinic performance (14%).

The figures, drawn from the company's Annual Report and Financial Statements for the period ended 31 December 2025 and filed at Companies House, were highlighted by SupplyIndex.io, a collective purchasing platform for independent medical, veterinary, optometry and allied health clinics. The company argues that the CPP Europe accounts illustrate a gap between the headline multiple that sellers are shown and the economic reality of what they receive, and when.

The mechanics behind a healthcare rollup

CPP Europe's results for its first reporting period show revenue of £13.3 million and gross profit of £8.0 million, a margin of approximately 60.5%. Administrative expenses of £12.7 million produced an operating loss of approximately £6.0 million and a reported EBITDA of negative £1.9 million. Adding back disclosed share-based payment charges and acquisition costs yields an illustrative adjusted EBITDA of approximately positive £0.8 million. The auditors concluded the going-concern basis remained appropriate following a refinancing that included a new £30 million banking facility agreed after the period end.

The accounts also disclose that some former owners hold B and C ordinary shares carrying dividend rights but no voting rights. Those shareholders cannot vote on a future sale of the business, on new share issuances, or on subsequent acquisitions, though separate contractual protections may exist outside the filed accounts.

"The decision is not simply whether the headline multiple looks attractive," said Peter Langdon of SupplyIndex.io. "It is also about what the seller retains, what becomes contingent and who controls the decisions that affect the remaining value."

The convergence angle: consolidation economics collide with independent healthcare

The healthcare rollup model is not unique to the UK clinic sector. The same acquisition architecture, combining modest upfront cash with shares in a private platform, multi-year earn-outs, and profit-participation arrangements, has structured deals across veterinary practices, dental chains, and optometry networks across Europe and North America over the past decade. Private equity has driven much of this consolidation wave, attracted by fragmented markets with recurring revenues and meaningful operational leverage at scale.

For cross-sector investors, the CPP Europe disclosures are a reminder that margin improvement in rollup strategies is rarely linear. The group's first-period administrative cost structure, which the accounts do not break into clinic-level and central components, illustrates a challenge common to platform businesses: the cost of the infrastructure required to deliver scale benefits often precedes those benefits by several financial periods. Investors who price healthcare rollups on projected EBITDA multiples absorb that timing risk along with the earn-out exposure carried by selling clinic owners.

SupplyIndex.io positions itself as an alternative route: aggregating purchasing demand across independent clinics without aggregating ownership. It is currently inviting founding members to review a collective merchant-services arrangement with a global payments provider, and says further collective opportunities covering indemnity insurance, utilities, and clinical-waste disposal are planned. Whether a purchasing collective can meaningfully replicate the structural cost advantages that a fully consolidated group commands at scale is an open question the platform has yet to answer with published numbers.

What the CPP Europe accounts do demonstrate clearly is that the economics of selling into a consolidator are more complex than a single headline multiple suggests. For clinic owners, and for the institutional investors backing the acquirers, the real negotiation is over how value is divided across time, performance, and control.